

## **Eir Ventures strengthens team – appoints three new Partners**

June 3, 2022: Eir Venture Partners, a life science venture capital fund with a presence in Stockholm (Sweden), Copenhagen (Denmark) and New Haven, CT (USA) is appointing three new Partners to the Investment team.

Eir Ventures I is a €125million fund backed by leading European Fund-of-fund investors. The Fund was launched 2020 and has since its inception built a portfolio of twelve life science companies.

Eir ventures has established itself as a well-respected professional investor in the Nordic life science ecosystem and will continue to build the organization and network to key stakeholders in the region. In accordance with this aim, Eir Ventures is expanding the team with three new partners.

*Dr Lene Gerlach, PhD* is an experienced Venture Capitalist specializing in Life Science investments. With more than 25 years' experience within the life science industry as a research scientist, patent attorney, business developer, and consultant on university spinouts, Lene has been Vice President in two biotech companies and has 8 years of direct venture capital experience. She has financed more than 35 companies, worked on numerous follow-up capital rounds and executed company exits. Lene comes with extensive board experience having headed 18 companies as Chairman and had 17 additional board member or observer roles. Lene also comes with a wide personal network within the European Life Science venture community, Nordic universities, healthcare start-up hubs and accelerator programs.

*Dr Alexander Mata* has a PhD in Cell and Molecular Biology and an MBA in Management. He started off his corporate life science career in the global pharma industry at Novartis and Bayer, where he held a number of strategic R&D positions. His most recent assignment was as healthcare Equity Analyst at Alecta, which has given him institutional experience in identifying and evaluating larger life science investments. Alexander joined Eir Ventures 2021.

*Dr Tobias Horneman-Thielcke MD LLB*, is a physician and holds a BA in Law. Tobias started his career working as a physician and later transferred to the pharmaceutical industry, where he spent several years in various regional and global leadership positions for Sanofi Genzyme and Y-mAbs. Tobias is experienced within rare diseases, immunology and oncology, developing and managing strategy, product launches and drug positioning with R&D. Tobias is also the founder of a medtech startup company, Connect2Treat.com, that digitalizes HCP and pharma interactions. Tobias joined Eir Ventures early 2022.

The three new Partners will join the *Founding Partners Magnus Persson MD PhD, Stephan Christgau PhD and Amanda Hayward PhD*. Concomitant with this expansion of the investment team, Mr Andreas Segerros will be leaving the firm to pursue an alternate professional role.